Aerovate Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Waltham, mass., march 27, 2024 (globe newswire) -- aerovate therapeutics, inc. (nasdaq: avte), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 american thoracic society (ats) international conference taking place may 17-22, 2024, in san diego, ca. the presentation will provide baseline characteristics from patients enrolled in the dose-ranging phase 2b portion of the inhaled imatinib pulmonary arterial hypertension clinical trial (impahct), a phase 2b/phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of av-101 in adults with pulmonary arterial hypertension.

Waltham, mass., march 25, 2024 (globe newswire) -- aerovate therapeutics, inc. (nasdaq: avte), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended december 31, 2023, and recent business highlights.

Waltham, mass., march 06, 2024 (globe newswire) -- aerovate therapeutics, inc. (nasdaq: avte), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its board of directors has elected current board member, habib dable, as chair of the board. mr. dable succeeds mark iwicki, who will continue to serve on the board.

Topline phase 2b data expected in june 2024 more than 120 sites around the world actively recruiting in the phase 3 portion of the impahct trial waltham, mass., nov. 20, 2023 (globe newswire) -- aerovate therapeutics, inc. (nasdaq: avte), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the phase 2b portion of the inhaled imatinib pulmonary arterial hypertension clinical trial (impahct) phase 2b/phase 3 study evaluating av-101, a novel dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (pah), has completed enrollment at 202 adult patients.

Waltham, mass., nov. 13, 2023 (globe newswire) -- aerovate therapeutics, inc. (nasdaq: avte), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended september 30, 2023, and recent business highlights.

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension.

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced that Company management will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, at 8:00 a.m. ET, which presentation will include an overview of AV-101 and the IMPAHCT Phase 2b/Phase 3 trial.

AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient enrollment in phase 2b PAH trial, and top-line Phase 2b data is expected by Q4 '23 or Q1 '24.

WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced that Company management will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, at 10:30 a.m. ET. The panel discussion will focus on respiratory diseases, including pulmonary arterial hypertension (PAH), the recent sotatercept phase 3 data, and an overview of AV-101 and the IMPAHCT Phase 2b/Phase 3 trial.

Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 or 1Q 2024, which we believe will be positive.

The stock price of Aerovate Therapeutics Inc (NASDAQ: AVTE) increased by over 19% today. These are some details you should know.

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, announced it has been added to the Russell 2000® Index, effective after the market's close today, following the recent Russell US Indexes annual reconstitution.

Here are the five companies that saw the biggest combined stock purchases from insiders during the week ended July 9.

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the closing of its upsized initial public offering of 9,984,463 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,302,321 additional shares of common stock, at a public offering price of $14.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Aerovate, were approximately $139...

Just shy of a full year after emerging from stealth mode, Aerovate Therapeutics Inc (NASDAQ: AVTE) is listing onto NASDAQ with an upsized offering. The company priced 8.68 million shares at $14, the midpoint of a $13 to $15 range.